October 12, 2006 – Genentech received approval for Avastin as a treatment for non-small cell lung cancer; Genzyme reported that earnings grew 22% before charges; Ambrilia Biopharma outlicensed its HIV/AIDS protease inhibitor program to Merck; Gene Logic will seek to rescue drugs that Lilly abandoned; Nabi completed enrollment in a trial of anti-smoking vaccine; Solvay and Wyeth asked the FDA to approve a new schizophrenia drug; Peregrine got the go-ahead for a trial in India of its brain cancer drug, and we review the unimpressive situation in the IPO sector. The Centient Biotech 200™ closed with an increase of 26 points at 3937, a .67% jump. More details...
